latanoprost and Lymphoma--B-Cell--Marginal-Zone

latanoprost has been researched along with Lymphoma--B-Cell--Marginal-Zone* in 1 studies

Other Studies

1 other study(ies) available for latanoprost and Lymphoma--B-Cell--Marginal-Zone

Article	Year
Use of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphoma. Ocular immunology and inflammation, 2010, Volume: 18, Issue:2 The clinical efficacy of rituximab therapy in systemic mucosa-associated lymphoid tissue (MALT) lymphoma with both periocular and intraocular involvement is described. Ophthalmic examination and radiologic imaging demonstrated tumor with bilateral periorbital, lacrimal, and subconjunctival infiltration, a pseudohypopyon in one eye, and extensive systemic lymph node involvement. Lymph node biopsy confirmed the pathologic findings of a low-grade MALT lymphoma. The patient had a complete remission within 3 months of starting rituximab therapy. A recurrence 6 months later remitted with a second round of rituximab therapy and the patient remained tumor-free at 1 year. Topics: Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Brimonidine Tartrate; Drug Therapy, Combination; Eye Neoplasms; Female; Glaucoma; Humans; Latanoprost; Loteprednol Etabonate; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Parotid Neoplasms; Prostaglandins F, Synthetic; Quinoxalines; Rituximab; Sulfonamides; Thiophenes; Timolol	2010

Article

Year

Use of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphoma.

Ocular immunology and inflammation, 2010, Volume: 18, Issue:2

The clinical efficacy of rituximab therapy in systemic mucosa-associated lymphoid tissue (MALT) lymphoma with both periocular and intraocular involvement is described. Ophthalmic examination and radiologic imaging demonstrated tumor with bilateral periorbital, lacrimal, and subconjunctival infiltration, a pseudohypopyon in one eye, and extensive systemic lymph node involvement. Lymph node biopsy confirmed the pathologic findings of a low-grade MALT lymphoma. The patient had a complete remission within 3 months of starting rituximab therapy. A recurrence 6 months later remitted with a second round of rituximab therapy and the patient remained tumor-free at 1 year.

Topics: Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Brimonidine Tartrate; Drug Therapy, Combination; Eye Neoplasms; Female; Glaucoma; Humans; Latanoprost; Loteprednol Etabonate; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Parotid Neoplasms; Prostaglandins F, Synthetic; Quinoxalines; Rituximab; Sulfonamides; Thiophenes; Timolol

2010